ULTRAPLACAD mid-term results: nanostructured surface architectures and preliminary plasmonic readers
After the first 21 months, the project ULTRAPLACAD is halfway, with important results already achieved. NESPRI and PEFSI nanostructure geometries have been identified. Probes for the selected all-RAS mutations and microRNAs have been synthesized. Candidate antigenic peptides for a-TAA detection have been defined. Attomolar detection of all-RAS mutations and femtomolar detection of microRNAs have been demonstrated. Besides the first version of NESPRI and PEFSI reader laboratory prototypes have been completed and the high-volume fabrication of nanostructured disposable chips has been demonstrated.
ULTRAPLACAD will develop a bimodal industrial prototype integrating novel surface plasmon resonance imaging (NESPRI) and plasmon-enhanced fluorescence (PEFSI) sensing technologies. The aim is to detect mutated DNAs, microRNAs and tumor autoantibodies (a-TAAs). The detection of all these molecular cancer biomarkers freely circulating in blood of colorectal cancer patients will be combined in a single device that will overcome hurdles and limitations of the currently available approaches.